Human CD62Ldim neutrophils identified as a separate subset by proteome profiling and in vivo pulse-chase labeling

Tamar Tak, Patrick Wijten, Marjolein Heeres, Peter Pickkers, Arjen Scholten, Albert J R Heck, Nienke Vrisekoop, Luke P Leenen, José A M Borghans, Kiki Tesselaar, Leo Koenderman, Tamar Tak, Patrick Wijten, Marjolein Heeres, Peter Pickkers, Arjen Scholten, Albert J R Heck, Nienke Vrisekoop, Luke P Leenen, José A M Borghans, Kiki Tesselaar, Leo Koenderman

Abstract

During acute inflammation, 3 neutrophil subsets are found in the blood: neutrophils with a conventional segmented nucleus, neutrophils with a banded nucleus, and T-cell-suppressing CD62Ldim neutrophils with a high number of nuclear lobes. In this study, we compared the in vivo kinetics and proteomes of banded, mature, and hypersegmented neutrophils to determine whether these cell types represent truly different neutrophil subsets or reflect changes induced by lipopolysaccharide (LPS) activation. Using in vivo pulse-chase labeling of neutrophil DNA with 6,6-2H2-glucose, we found that 2H-labeled banded neutrophils appeared much earlier in blood than labeled CD62Ldim and segmented neutrophils, which shared similar label kinetics. Comparison of the proteomes by cluster analysis revealed that CD62Ldim neutrophils were clearly separate from conventional segmented neutrophils despite having similar kinetics in peripheral blood. Interestingly, the conventional segmented cells were more related at a proteome level to banded cells despite a 2-day difference in maturation time. The differences between CD62Ldim and mature neutrophils are unlikely to have been a direct result of LPS-induced activation, because of the extremely low transcriptional capacity of CD62Ldim neutrophils and the fact that neutrophils do not directly respond to the low dose of LPS used in the study (2 ng/kg body weight). Therefore, we propose CD62Ldim neutrophils are a truly separate neutrophil subset that is recruited to the bloodstream in response to acute inflammation. This trial was registered at www.clinicaltrials.gov as #NCT01766414.

© 2017 by The American Society of Hematology.

Source: PubMed

3
Abonnieren